Many times, packaging design is developed with the objective of meeting immediate clinical trial requirements as cost efficiently as possible.  The drawback to that approach is that it can cost the company more in the long run. Ideally, primary contact clinical packaging should be close to mimicking commercial packaging using like for like materials.  A late stage change moving from 90 count bottles into 3 x 30 count blister packs require additional stability studies prior to implementation and or regulatory filings – costing time and money.

We have years of experience in working with companies in early start up to those with commercialized products.  We can help guide your organization helping you define your clinical packaging so that its very close to what you expect to use commercially, so new stability studies can be minimized or avoided.